Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several�…

The clinical relevance of T cells in the control of a diverse set of human cancers is now
beyond doubt. However, the nature of the antigens that allow the immune system to�…

Effective anti-tumour immunity in humans has been associated with the presence of T cells
directed at cancer neoantigens, a class of HLA-bound peptides that arise from tumour�…

Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance
antitumor immune responses, has led to important clinical advances and provided a new�…

T cell activation is a highly regulated process involving peptide–MHC engagement of the T
cell receptor and positive costimulatory signals. Upon activation, coinhibitory'checkpoints'�…

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival�…

Regulatory T (Treg) cells, an immunosuppressive subset of CD4+ T cells characterized by
the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a�…

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma�…

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for�…

Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung�…